Kimberly-Clark Acquires Kenvue in $2.1B Cost-Cutting Power Move

Kimberly-Clark has made a major move by acquiring Kenvue, the consumer health company behind well-known brands like Band-Aid and Tylenol. The deal is expected to bring in $2.1 billion in annual savings within three years. Known for its own household names such as Kleenex and Huggies, the company is also drawing attention for its strong dividend record and low share price.

Kimberly-Clark completed 2025 with modest growth, reporting a 1.7% rise in organic sales and a 3.2% increase in adjusted earnings per share. Looking ahead, the company forecasts 2% organic sales growth for 2026, with adjusted earnings per share expected to remain flat.

The acquisition of Kenvue marks a significant expansion beyond Kimberly-Clark's core paper products business. While financial details of Kenvue's performance since its 2023 spin-off from Johnson & Johnson remain undisclosed, the deal aligns with Kimberly-Clark's strategy to boost efficiency and shareholder value.

On January 27, 2026, the company raised its dividend for the 54th year in a row. This consistency, combined with a 5% dividend yield and a share price trading at just 13 times forward earnings, has positioned Kimberly-Clark as an attractive option for value-focused investors. Roughly two-thirds of its sales still come from North America, with the remainder generated internationally.

The Kenvue acquisition is set to deliver $2.1 billion in annual cost savings by 2028. With a long history of dividend increases and a low valuation, Kimberly-Clark remains a standout choice for investors seeking steady returns. The company's focus on efficiency and growth in both consumer health and paper products will shape its performance in the coming years.